Laboratory Considerations for Clinical Trials
Science:Life Sciences
In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.
Topics covered include:
- What health organizations are looking for that drives the selection of the next season's vaccine strains
- How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
- How the sequence data can inform the development of new types of vaccines and therapeutics
- The prospects for a vaccine that is effective across multiple strains and multiple seasons
- How NGS data differs from traditional Sanger sequencing data and what can be learned from that
You can learn more about this topic at www.q2labsolutions.com
More Episodes
Avoiding Canceled Tests in Pediatric Samples
2021-02-02
101
2021-02-02
101
Covid Vaccine Testing
2020-09-15
139
2020-09-15
139
Hybrid Assays for Protein Bioanalysis
2020-07-29
94
2020-07-29
94
High Throughput ADME Testing
2020-07-29
59
2020-07-29
59
Companion Diagnostic Strategies for Commercial Success
2019-02-26
90
2019-02-26
90
Bioanalysis for Immuno-oncology - Dr. Mike Brown
2019-02-12
48
2019-02-12
48
Anatomic Pathology
2019-02-05
74
2019-02-05
74
Get this podcast on your
phone, FREE
Create your
podcast in
minutes
- Full-featured podcast site
- Unlimited storage and bandwidth
- Comprehensive podcast stats
- Integrate with iTunes and Google
store - Make money with your podcast
It is Free
